About this episode
What are we to make of this large RCT of extended vs standard pelvic lymph node dissection (PLND) for prostate cancer?? Despite it not meeting its primary endpoint of improving biochemical recurrence, the authors now report in European Urology that it does reduce the incidence of distant metastases 10 years later! Go figure!
We chat with Dr Karim Touijer (MSKCC) and try to figure it out. We ask about data dredging, p-hacking and statistical shenanigans, and how adding two minutes and two extra lymph nodes to a PLND could possibly lead to reduced metastases.
Plus guest comments from Dr John Yaxley (Brisbane). What do you think??!! Will this change practice?? Will this change guidelines? Tune in and share your thoughts!
Even better on our YouTube channel
Links:
Paper in European Urology
Previous GU Cast with Karim discussing earlier paper (Feb 2022)
Get every episode summarized
Each time GU Cast | Urology Podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from GU Cast | Urology Podcast
Is Copper the new Gold??! Co-PSMA trial in European Urology
GU Cast | Urology Podcast
EAU Prostate Cancer Guideline Update
GU Cast | Urology Podcast
Journal club #7 | proPSMA and Penile Fractures(!)
GU Cast | Urology Podcast
ASPIRE-ing to answer the Triplet question! With Rana McKay and Deepak Kilari
GU Cast | Urology Podcast